Xeljanz 1 MG/ML Oral Solution
- RxCUI
- 2478437
- RxNorm name
- Xeljanz 1 MG/ML Oral Solution
- Display name
- Xeljanz 1 MG/ML Oral Solution
- Full name
- Xeljanz 1 MG/ML Oral Solution
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:22
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| XELJANZ | TOFACITINIB | U.S. Pharmaceuticals | 68e3d6b2-7838-4d2d-a417-09d919b43e13 | 2026-07-13 | Boxed warning, Warnings, Adverse reactions | 2478437 |
| XELJANZ XR | TOFACITINIB | Pfizer Laboratories Div Pfizer Inc | cf74ba2f-afc5-4baa-8594-979c889a5831 | 2026-07-12 | Boxed warning, Warnings, Adverse reactions | 2478437 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| cf74ba2f-afc5-4baa-8594-979c889a5831 | Xeljanz 1 MG/ML Oral Solution | SY | 53 | These highlights do not include all the information needed to use XELJANZ/XELJANZ XR safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR. XELJANZ ® (tofacitinib) tablets, for oral use XELJANZ ® (tofacitinib) oral solution XELJANZ ® XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2012 | 20260312 |
| cf74ba2f-afc5-4baa-8594-979c889a5831 | Xeljanz 1 MG/mL Oral Solution | PSN | 53 | These highlights do not include all the information needed to use XELJANZ/XELJANZ XR safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR. XELJANZ ® (tofacitinib) tablets, for oral use XELJANZ ® (tofacitinib) oral solution XELJANZ ® XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2012 | 20260312 |
| cf74ba2f-afc5-4baa-8594-979c889a5831 | tofacitinib 1 MG/ML Oral Solution [Xeljanz] | SBD | 53 | These highlights do not include all the information needed to use XELJANZ/XELJANZ XR safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR. XELJANZ ® (tofacitinib) tablets, for oral use XELJANZ ® (tofacitinib) oral solution XELJANZ ® XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2012 | 20260312 |
| 68e3d6b2-7838-4d2d-a417-09d919b43e13 | Xeljanz 1 MG/mL Oral Solution | PSN | 17 | These highlights do not include all the information needed to use XELJANZ/XELJANZ XR safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR. XELJANZ ® (tofacitinib) tablets, for oral use XELJANZ ® (tofacitinib) oral solution XELJANZ ® XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2012 | 20260327 |
| 68e3d6b2-7838-4d2d-a417-09d919b43e13 | tofacitinib 1 MG/ML Oral Solution [Xeljanz] | SBD | 17 | These highlights do not include all the information needed to use XELJANZ/XELJANZ XR safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR. XELJANZ ® (tofacitinib) tablets, for oral use XELJANZ ® (tofacitinib) oral solution XELJANZ ® XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2012 | 20260327 |
| 68e3d6b2-7838-4d2d-a417-09d919b43e13 | Xeljanz 1 MG/ML Oral Solution | SY | 17 | These highlights do not include all the information needed to use XELJANZ/XELJANZ XR safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR. XELJANZ ® (tofacitinib) tablets, for oral use XELJANZ ® (tofacitinib) oral solution XELJANZ ® XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2012 | 20260327 |